

Appendices

CONTENTS

Appendix A - Endoscopy Families 115

Appendix B - Bundled Services116

Appendix C - Bundled Supplies117

Appendix D - Non-Covered Codes and Modifiers 121

Appendix E - Modifiers that Affect Payment137

Appendix F - Anesthesia Services Paid with RBRVS141

Appendix G - Outpatient Drug Formulary143

Appendix H - Documentation Requirements.....157

APPENDIX E

MODIFIERS THAT AFFECT PAYMENT

Only modifiers that affect payment are listed in this section. Refer to current CPT® and HCPCS books for complete modifier descriptions and instructions.

CPT® MODIFIERS

-22 Unusual services

Procedures with this modifier may be individually reviewed prior to payment. A report is required for this review. Payment varies based on the report submitted.

-24 Unrelated evaluation and management (E/M) services by the same physician during a postoperative period

Used to indicate an evaluation and management service unrelated to the surgical procedure was performed during a postoperative period. *Documentation must be submitted with the billing form when this modifier is used.* Payment is made at one hundred percent of the fee schedule level or billed charge, whichever is less.

-25 Significant, separately identifiable evaluation and management (E/M) service by the same physician on the day of a procedure

Payment is made at one hundred percent of the fee schedule level or billed charge, whichever is less. Refer to the Professional Services section for information on the use of modifier -25.

-26 Professional component

Certain procedures are a combination of the professional (-26) and technical (-TC) components. This modifier should be used when only the professional component is performed. When a global service is performed, neither the -26 nor the -TC modifier should be used.

-50 Bilateral surgery

The bilateral modifier identifies cases where a procedure typically performed on one side of the body is, in fact, performed on both sides of the body. Payment is made at one hundred fifty percent of the global surgery fee for the procedure. Providers must bill using two line items on the bill form. The modifier -50 should be applied to the second line item.

-51 Multiple surgery

For procedure codes that represent multiple surgical procedures, payment is made based on the fee schedule allowance associated with that code. Refer to the global surgery rules for additional information.

-52 Reduced services

Payment is made at the fee schedule level or billed charge, whichever is less.

-53 Discontinued services

CMS has established reduced RVUs for CPT® code 45378 when billed with modifier -53. The department prices this code-modifier combination according to those RVUs.

- 54 Surgical care only ⁽¹⁾**
When one physician performs a surgical procedure and another provides preoperative and/or postoperative management.
- 55 Postoperative management only ⁽¹⁾**
When one physician performs the postoperative management and another physician has performed the surgical procedure.
- 56 Preoperative management only ⁽¹⁾**
When one physician performs the preoperative care and evaluation and another physician performs the surgical procedure.
(1) **When providing less than the global surgical package providers should use modifiers -54, -55, and -56.** These modifiers are designed to ensure that the sum of all allowances for all providers does not exceed the total allowance for the global surgery period. These modifiers allow direct payment to the provider of each portion of the global surgery services.
- 57 Decision for surgery**
Used only when the decision for surgery was made during the preoperative period of a surgical procedure with a global surgery follow-up period. It should not be used with visits furnished during the global period of minor procedures (0-10 day global period) unless the purpose of the visit is a decision for major surgery. Separate payment should be made even if the visit falls within the global surgery period. No separate documentation is needed when submitting a billing form with this modifier.
- 60 Altered Surgical Field**
Procedures with this modifier may be individually reviewed prior to payment. A report is required for this review. Payment varies based on the report submitted.
- 62 Two surgeons**
For surgery requiring the skills of two surgeons (usually with a different specialty), each surgeon is paid at 62.5% of the global surgical fee. No payment is made for an assistant-at-surgery in these cases.
- 66 Team surgery**
Used when highly complex procedures are carried out by a surgical team. This may include the concomitant services of several physicians, often of different specialties, other highly skilled, specially trained personnel, and various types of complex equipment. Procedures with this modifier are reviewed and priced on an individual basis. Supporting documentation is required for this review.
- 78 Return to the operating room for a related procedure during the postoperative period**
Payment is made at one hundred percent of the fee schedule level or billed amount, whichever is less.
- 79 Unrelated procedure or service by the same physician during the postoperative period**
Use of this modifier allows separate payment for procedures not associated with the original surgery. Payment is made at one hundred percent of the fee schedule level or billed amount, whichever is less.

-80 Assistant surgeon ⁽²⁾

-81 Minimum assistant surgeon ⁽²⁾

-82 Assistant surgeon (when qualified resident surgeon not available) ⁽²⁾

(2) **Assistant Surgeon Modifiers.** Physicians who assist the primary physician in surgery should use modifiers -80, -81 or -82 depending on the medical necessity. Payment for procedures with these modifiers is made at the billed charge or twenty percent of the global surgery amount for the procedure, whichever is less. Refer to the assistant surgeon indicator in the Professional Services Fee Schedule to determine if assistant surgeon fees are payable.

-91 Repeat clinical diagnostic laboratory test performed on the same day to obtain subsequent reportable test values(s) (separate specimens taken in separate encounters)

Payment will be made for repeat test(s) performed for the same patient on the same day when specimen(s) have been taken from separate encounters. Test(s) normally performed as a series, e.g. glucose tolerance test do not qualify as separate encounters. The medical necessity for repeating the test(s) must be documented in the patient record.

-99 Multiple modifiers

This modifier should only be used when two or more modifiers affect payment.

Payment is based on the policy associated with each individual modifier that describes the services performed. For billing purposes, only modifier -99 should go in the modifier column, with the individual descriptive modifiers that affect payment listed elsewhere on the billing form.

HCPCS MODIFIERS

-GT Teleconsultations via interactive audio and video telecommunication systems

Payment policies for teleconsultations are located in the Professional Services section.

-LT Left side

Although this modifier does not affect payment, it should be used when billing for bilateral services. This will help reduce duplicate bills and minimize payment delays.

-RT Right side

Although this modifier does not affect payment, it should be used when billing for bilateral services. This will help reduce duplicate bills and minimize payment delays.

-SG Ambulatory surgical center (ASC) facility service

Bill the appropriate CPT[®] surgical code(s) adding this modifier -SG to each surgery code.

-TC Technical component

Certain procedures are a combination of the professional (-26) and technical (-TC) components. This modifier should be used when only the technical component is performed. When a global service is performed, neither the -26 nor -TC modifier should be used. Refer to the CPT[®] modifier section for the use of the -26 modifier.

LOCAL MODIFIER

-1S Surgical dressings for home use

Bill the appropriate HCPCS code for each dressing item using this modifier -1S for each item. Use this modifier to bill for surgical dressing supplies dispensed for home use.

APPENDIX F

ANESTHESIA SERVICES PAID WITH RBRVS

Do not rely solely on the descriptions given in the appendices for complete coding information. Refer to a current CPT® or HCPCS book for complete coding information.

PAIN MANAGEMENT AND NERVE BLOCK CODES

| CPT® Code | Abbreviated Description |
|----------------------|-----------------------------------|
| 01996 | Manage daily drug therapy |
| 20526 | Ther injection, carpal tunnel |
| 20550 | Inject tendon/ligament/cyst |
| 20551 | Inject tendon origin/insert |
| 20552 | Inject trigger point, 1 or 2 |
| 20553 | Inject trigger points, >3 |
| 20600 | Drain/inject, joint/bursa |
| 20605 | Drain/inject, joint/bursa |
| 20610 | Drain/inject, joint/bursa |
| 20612 | Aspiration and/or inj of ganglion |
| 27096 | Inject sacroiliac joint |
| 61790 | Treat trigeminal nerve |
| 62263 | Lysis epidural adhesions |
| 62264 | Perc lysis of epidural adhesions |
| 62270 | Spinal fluid tap, diagnostic |
| 62272 | Drain spinal fluid |
| 62273 | Treat epidural spine lesion |
| 62281 | Treat spinal cord lesion |
| 62282 | Treat spinal canal lesion |
| 62284 | Injection for myelogram |
| 62290 | Inject for spine disk x-ray |
| 62291 | Inject for spine disk x-ray |
| 62310 | Inject spine c/t |
| 62311 | Inject spine l/s (cd) |
| 62318 | Inject spine w/cath, c/t |
| 62319 | Inject spine w/cath l/s (cd) |
| 64400 | Injection for nerve block |
| 64402 | Injection for nerve block |
| 64405 | Injection for nerve block |
| 64408 | Injection for nerve block |
| 64410 | Injection for nerve block |
| 64412 | Injection for nerve block |
| 64413 | Injection for nerve block |
| 64415 | Injection for nerve block |
| 64416 | Inj anesth agent; brachial plexus |

| CPT® Code | Abbreviated Description |
|----------------------|---------------------------------|
| 64417 | Injection for nerve block |
| 64418 | Injection for nerve block |
| 64420 | Injection for nerve block |
| 64421 | Injection for nerve block |
| 64425 | Injection for nerve block |
| 64430 | Injection for nerve block |
| 64435 | Injection for nerve block |
| 64445 | Injection for nerve block |
| 64446 | Inj anesth agent; sciatic nerve |
| 64447 | Inj anesth agent; femoral nerve |
| 64448 | Inj anesth agent; femoral nerve |
| 64450 | Injection for nerve block |
| 64470 | Inj paravertebral c/t |
| 64472 | Inj paravertebral c/t add-on |
| 64475 | Inj paravertebral l/s |
| 64476 | Inj paravertebral l/s add-on |
| 64479 | Inj foramen epidural c/t |
| 64480 | Inj foramen epidural add-on |
| 64483 | Inj foramen epidural l/s |
| 64484 | Inj foramen epidural add-on |
| 64505 | Injection for nerve block |
| 64508 | Injection for nerve block |
| 64510 | Injection for nerve block |
| 64520 | Injection for nerve block |
| 64530 | Injection for nerve block |
| 64550 | Apply neurostimulator |
| 64553 | Implant neuroelectrodes |
| 64555 | Implant neuroelectrodes |
| 64560 | Implant neuroelectrodes |
| 64565 | Implant neuroelectrodes |
| 64573 | Implant neuroelectrodes |
| 64575 | Implant neuroelectrodes |
| 64577 | Implant neuroelectrodes |
| 64580 | Implant neuroelectrodes |
| 64585 | Revise/remove neuroelectrode |

| CPT® Code | Abbreviated Description |
|----------------------|--------------------------------|
| 64590 | Implant neuroreceiver |
| 64595 | Revise/remove neuroreceiver |
| 64600 | Injection treatment of nerve |
| 64605 | Injection treatment of nerve |
| 64610 | Injection treatment of nerve |
| 64612 | Destroy nerve, face muscle |
| 64613 | Destroy nerve, spine muscle |
| 64620 | Injection treatment of nerve |
| 64622 | Destr paravertebrl nerve l/s |
| 64623 | Destr paravertebral n add-on |

| CPT® Code | Abbreviated Description |
|----------------------|--------------------------------|
| 64626 | Destr paravertebrl nerve c/t |
| 64627 | Destr paravertebral n add-on |
| 64630 | Injection treatment of nerve |
| 64640 | Injection treatment of nerve |
| 64680 | Injection treatment of nerve |
| 64802 | Remove sympathetic nerves |
| 64804 | Remove sympathetic nerves |
| 64809 | Remove sympathetic nerves |
| 64818 | Remove sympathetic nerves |

OTHER ACCEPTED CODES

| CPT® Code | Abbreviated Description |
|----------------------|--------------------------------|
| 31500 | Insert emergency airway |
| 36425 | Establish access to vein |
| 36489 | Insertion of catheter, vein |
| 36491 | Insertion of catheter, vein |
| 36600 | Withdrawal of arterial blood |
| 36620 | Insertion catheter, artery |
| 36625 | Insertion catheter, artery |
| 63600 | Remove spinal cord lesion |
| 76000 | Fluoroscope examination |
| 76003 | Fluoroscope exam, extensive |
| 76005 | Fluoroguide for spine inject |
| 76496 | Unlisted fluoroscopic proc |
| 93503 | Insert/place heart catheter |

APPENDIX G

OUTPATIENT DRUG FORMULARY

The following is a list of the therapeutic classes (TCC) and their status in L&I's formulary. In most cases, the status is class specific rather than drug specific. An example of an exception to this general rule is therapeutic class code TCC – H2D Barbiturates. Phenobarbital is the only drug in the class that L&I will allow.

Please keep the following points in mind about the formulary:

- This is an outpatient formulary. Many of the drugs in the denied category are appropriate for in- and outpatient surgery and emergency room, clinic or office settings, and are covered when billed appropriately.
- Some drugs in the denied category may be allowed under certain circumstances. These will be addressed on a case-by-case basis.
- Utilization of drugs in the authorized category is subject to department policy and appropriateness for the accepted conditions.

KEY TO STATUS AND REPRESENTATIVE DRUG INDICATORS:

Status:

- A = Allowed
 PA = Prior Auth required
 D = Denied
 O = Other (Will not pay through L&I's Point-of-Sale System)

Representative Drug:

Blank – Self-explanatory or used mainly for compound drugs.

* No drugs currently listed in the therapeutic class.

COMPOUND DRUGS

| STATUS | TCC | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|-------------------------------|---------------------|
| PA | 000 | COMPOUND DRUGS | |

A CARDIOVASCULAR SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| PA | A1A | DIGITALIS GLYCOSIDES | LANOXIN |
| A | A1B | XANTHINES | THEOPHYLLINE |
| D | A1C | INOTROPIC DRUGS | DOBUTAMINE |
| A | A1D | GENERAL BRONCHODILATOR AGENTS | BRONKAID MIST |
| PA | A2A | ANTIARRHYTHMICS | MEXILETINE HCL |
| PA | A4A | HYPOTENSIVES-VASODILATORS | HYTRIN |
| PA | A4B | HYPOTENSIVES-SYMPATHOLYTIC | CLONIDINE HCL |
| PA | A4C | HYPOTENSIVES-GANGLIONIC BLOCKERS | INVERSINE |
| PA | A4D | HYPOTENSIVES-ANGIOTENSIN CONV ENZYME BLOCKERS | ZESTRIL |
| PA | A4E | HYPOTENSIVES-VERATRUM ALKALOIDS | * |
| PA | A4F | HYPOTENSIVES, ANGIOTENSIN RECEPTOR ANTAGONIST | COZAAR |
| PA | A4K | ACE INHIBITOR/CA CHANNEL BLOCKER COMBINATION | LOTREL |
| PA | A4Y | HYPOTENSIVES-MISCELLANEOUS | ZIAC |
| D | A6U | CARDIOVASCULAR DIAGNOSTICS | |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|----------------------|
| D | A6V | CARDIOVASCULAR DIAGNOSTICS - NON RADIOPAQUE | |
| PA | A7A | ARTERIOLAR VASOCONSTRICTORS | * |
| PA | A7B | CORONARY VASODILATORS | IMDUR |
| PA | A7C | PERIPHERAL VASODILATORS | ERGOLOID MESYLATES |
| PA | A7E | VASODILATORS-MISCELLANEOUS | PROSTIN VR PEDIATRIC |
| PA | A7F | VEINOTONIC/VASCULOPROTECTORS | * |
| D | A7H | VASOACTIVE NATRIURETIC PEPTIDES | NATRECOR |
| D | A8O | VENOSCLEROSING AGENTS | ETHAMOLIN |
| PA | A9A | CALCIUM CHANNEL BLOCKING AGENTS | VERAPAMIL HCL |

B RESPIRATORY SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| A | B0A | MISCELLANEOUS RESPIRATORY INHALANTS | SODIUM CHLORIDE |
| D | B0P | INERT GASES | |
| D | B1A | LUNG SURFACTANTS | SURVANTA |
| D | B1B | PULM ANTIHYPERT, ENDOTHELIN RECEPT ANTAGONST-TYPE | TRACLEER |
| A | B3A | MUCOLYTICS | MUCOMYST |
| A | B3J | EXPECTORANTS | GUAIFENESIN |
| A | B3K | COUGH AND COLD PREPARATIONS | DIMETAPP |
| D | B3M | RESPIRATORY TRACT RADIOPAQUE DIAGNOSTICS | |

C ELECTROLYTE BALANCING SYS/METABOLIC SYS/NUTRITION

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|----------------------|
| A | C0B | WATER | WATER FOR INHALATION |
| D | C0C | DRUGS USED TO TREAT ACIDOSIS | THAM |
| PA | C0D | ANTIALCOHOLIC PREPARATIONS | DISULFIRAM |
| PA | C0K | BICARBONATE PRODUCING/CONTAINING AGENTS | SODIUM ACETATE |
| PA | C1A | ELECTROLYTE DEPLETERS | KAYEXALATE |
| PA | C1B | SODIUM REPLACEMENT | |
| PA | C1D | POTASSIUM REPLACEMENT | |
| PA | C1F | CALCIUM REPLACEMENT | |
| PA | C1H | MAGNESIUM REPLACEMENT | |
| PA | C1P | PHOSPHATE REPLACEMENT | |
| PA | C1W | ELECTROLYTE REPLACEMENT | |
| D | C2H | RESPIRATORY GASES | |
| PA | C3B | IRON REPLACEMENT | |
| PA | C3C | ZINC REPLACEMENT | |
| PA | C3H | IODINE REPLACEMENT | |
| PA | C3M | MISCELLANEOUS MINERAL REPLACEMENT | |
| PA | C4G | INSULINS | |
| PA | C4K | HYPOGLYCEMICS, INSULIN-RELEASE STIM. TYPE | GLYBURIDE |
| PA | C4L | HYPOGLYCEMICS, BIGUANIDE TYPE (N-S) | GLUCOPHAGE |
| PA | C4M | HYPOGLYCEMICS, ALPHA-GLUCOSIDASE INHIB. TYPE (N-S) | PRECOSE |
| PA | C4N | HYPOGLYCEMICS, INSULIN-RESPONSE ENHANCER (N-S) | REZULIN |
| PA | C4O | HYPOGLYCEMICS, ABSORPTION MODIFIER, UNSPECIFIED | * |
| PA | C4P | HYPOGLYCEMICS, UNSPECIFIED MECHANISM | * |
| PA | C4Q | HYPOGLYCEMICS, COMBINATION | * |
| PA | C5A | CARBOHYDRATES | DEXTROSE IN WATER |
| PA | C5B | PROTEIN REPLACEMENT | L-LYSINE |
| D | C5C | INFANT FORMULAS | ENFAMIL |
| D | C5D | DIET FOODS | * |
| D | C5E | GERIATRIC SUPPLEMENTS | SOD-K |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| D | C5F | MISCELLANEOUS FOOD SUPPLEMENTS | SUSTACAL |
| D | C5G | FOOD OILS | MCT OIL |
| A | C5H | NUCLEIC ACID SUPPLEMENTS | ADENSNE TRIPHOSPHAT |
| A | C5J | IV SOLUTIONS: DEXTROSE/WATER | |
| A | C5K | IV SOLUTIONS: DEXTROSE/SALINE | |
| A | C5L | IV SOLUTIONS: DEXTROSE/RINGERS | |
| A | C5M | IV SOLUTIONS: DEXTROSE/LACTATED RINGERS | |
| A | C5O | SOLUTIONS, MISCELLANEOUS | |
| D | C5Q | TONICS | * |
| D | C5U | NUTRITIONAL THERAPY, GLUCOSE INTOLERANCE | GLUCERNA |
| D | C6A | VITAMIN A PREPARATIONS | |
| D | C6B | VITAMIN B PREPARATIONS | |
| PA | C6C | VITAMIN C PREPARATIONS | |
| D | C6D | VITAMIN D PREPARATIONS | |
| D | C6E | VITAMIN E PREPARATIONS | |
| D | C6F | PRENATAL VITAMIN PREPARATIONS | |
| D | C6G | GERIATRIC VITAMIN PREPARATIONS | |
| D | C6H | PEDIATRIC VITAMIN PREPARATIONS | |
| D | C6J | BIOFLAVONOIDS | |
| PA | C6K | VITAMIN K PREPARATIONS | MEPHYTON |
| PA | C6L | VITAMIN B12 PREPARATIONS | |
| PA | C6M | FOLIC ACID PREPARATIONS | |
| D | C6N | NIACIN PREPARATIONS | |
| D | C6P | PANTHENOL PREPARATIONS | |
| D | C6Q | VITAMIN B6 PREPARATIONS | |
| D | C6R | VITAMIN B2 PREPARATIONS | |
| D | C6T | VITAMIN B1 PREPARATIONS | |
| D | C6Z | MISCELLANEOUS MULTIVITAMIN PREPARATIONS | |
| D | C7A | PURINE INHIBITORS | ALLOPURINOL |
| A | C7B | DECARBOXYLASE INHIBITORS | * |
| A | C7C | DIPEPTIDASE INHIBITORS | * |
| D | C7D | METABOLIC DEFICIENCY AGENTS | CYSTADANE |
| D | C7E | APPETITE STIMULANTS | PERIAVIT |
| A | C8A | METALLIC POISON ANTIDOTES | CUPRIMINE |
| A | C8B | ACID AND ALKALI POISON ANTIDOTES | METHYLENE BLUE |
| A | C8D | AGRICULTURAL POISON ANTIDOTES | PROTOPAM CL |
| A | C8E | MISCELLANEOUS ANTIDOTES | DIGIBIND |

D BILIARY SYSTEM/GASTRO-INTESTINAL SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|----------------------|
| D | D0U | GASTROINTESTINAL RADIOPAQUE DIAGNOSTICS | |
| D | D1A | PERIODONTAL COLLAGENASE INHIBITORS | PERIOSTAT |
| D | D1D | DENTAL SUPPLIES | TRIAMCINLNE ACETNIDE |
| D | D2A | FLUORIDE PREPARATIONS | PREVIDENT |
| D | D2D | TOOTH ACHE PREPARATIONS | CLOVE OIL |
| D | D2M | MISCELLANEOUS DENTAL PREPARATIONS | * |
| A | D4A | ACID REPLACEMENT | ACIDUTEX |
| A | D4B | ANTACIDS | MAALOX |
| A | D4C | AGENTS FOR STOMATOLOGICAL USE | DEBACTEROL |
| A | D4D | ANTIDIARRHEAL MICROORGANISMS AGENTS | * |
| A | D4E | ANTIULCER PREPARATIONS | CARAFATE |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| D | D4F | ANTIULCER -- H. PYLORI AGENTS | HELIDAC THERAPY |
| A | D4G | GASTRIC ENZYMES | LACTASE |
| A | D4H | ORAL MUCOSITIS/STOMATITIS AGENTS | ORAKOTE |
| A | D4I | ORAL MUCOSITIS/STOMATITIS ANTIINFLAMMATORY AGENTS | APHTHASOL |
| A | D4K | GASTRIC ACID SECRETION REDUCER | PRILOSEC |
| A | D4N | ANTIFLATULENTS | SIMETHICONE |
| D | D4O | GASTROINTEST ULTRASND IMAGE ENHNCING ADJUNCT, DIAG | SONO RX |
| A | D4Q | DIGESTIVE AGENTS, OTHER | IMUZYME |
| D | D4T | GASTRIC FUNCTION DIAGNOSTICS | |
| D | D4U | GASTRIC FUNCTION RADIOPAQUE DIAGNOSTICS | |
| D | D5A | FAT ABSORPTION DECREASING AGENTS | XENICAL |
| A | D5P | INTESTINAL ADSORBENTS AND PROTECTIVES | KAOPECTATE |
| PA | D6A | DRUGS TO TRT CHRONIC INFLAMM DISEASES OF THE COLON | REMICADE |
| D | D6C | IRRITABLE BOWEL SYND. AGENT, 5HT-3 ANTAGONIST-TYPE | LOTIRONEX |
| A | D6D | ANTIDIARRHEALS | LOMOTIL |
| D | D6E | IRRITABLE BOWEL SYNDROME AGTS, 5HT-4 PARTIAL AGONIST | ZELFORM |
| PA | D6F | DRUGS TO TRT CHRONIC INFLAMM COLON DX 5 – AMINOSAL | ASACOL |
| A | D6H | HEMORRHOIDAL AGENTS | * |
| A | D6S | LAXATIVES AND CATHARTICS | DOCUSATE SODIUM |
| A | D7A | BILE SALTS | DECHOLIN |
| A | D7B | CHOLERETICS | KINEVAC |
| D | D7C | HEPATIC DIAGNOSTICS | |
| D | D7D | DRUGS TO TREAT HEREDITARY TYROSINEMIA | ORFADIN |
| PA | D7J | HEPATIC DYSFUNCTION PREVENTIVE/THERAPY AGENTS | * |
| A | D7L | BILE SALT INHIBITORS | QUESTRAN |
| D | D7T | BILIARY DIAGNOSTICS | |
| D | D7U | BILIARY DIAGNOSTICS, RADIOPAQUE | |
| A | D8A | PANCREATIC ENZYMES | PANCREASE |
| D | D8B | PANCREATIC DIAGNOSTICS | |
| A | D9A | AMMONIA INHIBITORS | BUPHENYL |

F MALE GENITAL SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|-------------------------------|---------------------|
| PA | F1A | ANDROGENIC AGENTS | DEPO-TESTOSTERONE |
| PA | F2A | DRUGS TO TREAT IMPOTENCY | MUSE |

G FEMALE GENITAL SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| D | G0U | UTERINE RADIOPAQUE DIAGNOSTIC AGENTS | |
| D | G1A | ESTROGENIC AGENTS | PREMARIN |
| D | G1B | ESTROGEN/ANDROGEN COMBINATION PREPARATIONS | ESTRATEST |
| D | G2A | PROGESTATIONAL AGENTS | PROVERA |
| D | G3A | OXYTOCICS | PITOCIN |
| D | G8A | CONTRACEPTIVES, ORAL | LOESTRIN FE |
| D | G8B | CONTRACEPTIVES, IMPLANTABLE | NORPLANT SYSTEM |
| D | G8C | CONTRACEPTIVES, INJECTABLE | DEPO-PROVERA |
| PA | G8D | ABORTIFACIENT, PROGESTRNE RECEPT ANTAGONIST TYPE | MIFEPREX |
| D | G8F | CONTRACEPTIVES, TRANSDERMAL | ORTHO EVRA |
| D | G9A | CONTRACEPTIVES, INTRAVAGINAL | CONCEPTROL GEL |
| D | G9B | CONTRACEPTIVES,INTRAVAGINAL, SYSTEMIC | NUVARING |

H NERVOUS SYSTEM (EXCEPT AUTONOMIC)

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|-----------------------|
| A | H0A | LOCAL ANESTHETICS | LIDOCAINE |
| D | H0E | AGENTS TO TREAT MULTIPLE SCLEROSIS | COPAXONE |
| D | H1U | CEREBRAL SPINAL RADIOPAQUE DIAGNOSTICS | |
| PA | H2A | CENTRAL NERVOUS SYSTEM STIMULANTS | CYLERT |
| D | H2B | GENERAL ANESTHETICS, INHALANT | HALOTHANE |
| D | H2C | GENERAL ANESTHETICS, INJECTABLE | PENTOTHAL |
| A | H2D | BARBITURATES (Phenobarbital Only) | NEMBUTAL |
| A | H2E | NON-BARBITURATE, SEDATIVE-HYPNOTICS | AMBIEN |
| A | H2F | ANTI-ANXIETY DRUGS | DIAZEPAM |
| A | H2G | ANTI-PSYCHOTICS, PHENOTHIAZINES | PERPHENAZINE |
| A | H2H | MONOAMINE OXIDASE (MAO) INHIBITORS | * |
| A | H2J | ANTIDEPRESSANTS O.U. | * |
| A | H2K | ANTIDEPRESSANT COMBINATIONS O.U. | * |
| A | H2L | ANTI-PSYCHOTICS, NON-PHENOTHIAZINES | HALDOL |
| A | H2M | ANTI-MANIA DRUGS | LITHIUM CARBONATE |
| A | H2R | ANTI-PRURITICS | * |
| A | H2S | SEROTONIN SPEC REUPTAKE INHIBITOR (SSRI'S) | PROZAC |
| D | H2T | ALCOHOL-SYSTEMIC USE | |
| A | H2U | TRICYCLIC ANTIDEPRESSANTS & RELATED NON-SRI | AMITRIPTYLINE HCL |
| PA | H2V | ANTI-NARCOLEPSY/ANTI-HYPERKINESIS AGENTS | METHYLPHENIDATE HCL |
| A | H2W | TRICYCLIC ANTIDEPRESSANT/PHENOTHIAZINE COMBOS | ETRAFON 2-10 |
| A | H2X | TRICYCLIC ANTIDEPRESSANT/BENZODIAZEPINE COMBOS | LIMBITROL |
| A | H2Y | TRICYCLIC ANTIDEPRESSANT/NON-PHENOTHIAZINE COMBOS | * |
| A | H2Z | BENZODIAZEPINE ANTAGONISTS | ROMAZICON |
| A | H3A | ANALGESICS, NARCOTICS | HYDROCODONE/APAP |
| A | H3C | ANALGESICS, NON-NARCOTICS | DURACLON |
| A | H3D | SALICYLATE ANALGESICS | ASPIRIN, BUTAL CMPND |
| A | H3E | ANALGESIC/ANTIPYRETICS, NON-SALICYLATE | APAP, BUTALBITAL/APAP |
| PA | H3F | ANTIMIGRAINE PREPARATIONS | IMITREX |
| A | H3G | MISCELLANEOUS ANALGESICS | * |
| D | H3H | ANALGESICS NARCOTIC, ANESTHETIC ADJUNCT | FENTANYL CITRATE |
| A | H3T | NARCOTIC ANTAGONISTS | NALOXONE |
| A | H4B | ANTICONVULSANTS | NEURONTIN |
| D | H4T | HALLUCINOGENS | * |
| D | H5A | NEUROTONICS/CEREBROVASCULAR ACCIDENT AGENTS | * |
| A | H5B | NEUROPATHIC AGENTS | * |
| PA | H6A | ANTIPARKINSONISM DRUGS, OTHER | SINEMET CR |
| A | H6B | ANTIPARKINSONISM DRUGS, ANTICHOLINERGIC | BENZTROP MESYLATE |
| A | H6C | ANTITUSSIVE, NON-NARCOTIC | ROBITUSSIN |
| A | H6E | EMETICS | IPECAC |
| A | H6H | SKELETAL MUSCLE RELAXANTS | FLEXERIL |
| D | H6I | AMYOTROPHIC LATERAL SCLEROSIS AGENTS | RILUTEK |
| A | H6J | ANTI-EMETICS | MECLIZINE HCL |
| D | H6L | MOVEMENT DISORDERS (DRUG THERAPY) | * |
| A | H6N | ANTITUSSIVES, NARCOTIC | * |
| A | H7A | TRICYCLIC ANTIDEPRESSANT/PHENO/BENZO COMB. | * |
| A | H7B | ALPHA-2 RECEPTOR ANTAGONISTS | REMERON |
| A | H7C | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIB (SNRIS) | EFFEXOR |
| PA | H7D | NOREPINEPHRINE AND DOPAMINE REUPTAKE INHIB (NDRIS) | WELLBUTRIN |
| A | H7E | SEROTONIN-2 ANTAGONIST/REUPTAKE INHIB (SARIS) | TRAZODONE |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| A | H7F | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITR (SEL-NARI) | * |
| A | H7G | SEROTONIN AND DOPAMINE REUPTAKE INHIB (SDRIS) | * |
| A | H7H | SSRI & ERGOT COMB. (SSRI/ERGOT COMB.) | * |
| A | H7I | ANTIDEPRESSANT O.U./BARB/BELLADONNA COMBINATIONS | * |
| A | H7J | MAOIS - NON-SELECTIVE & IRREVERSIBLE | NARDIL |
| A | H7K | MAOIS - A SELECTIVE & REVERSIBLE (RIMA) | * |
| A | H7L | MAOI N-S & IRREVERSIBLE/PHENOTHIAZINE COMBINATIONS | * |
| A | H7M | ANTIDEPRESSANT O.U./CARBAMATE ANXIOLYTIC COMBOS | * |
| PA | H7N | SMOKING DETERRENTS, OTHER | ZYBAN |
| A | H7O | ANTIPSYCHOTIC, DOPAMINE ANTAGONIST, BUTYROPHEN | HALOPERIDOL |
| A | H7P | ANTIPSYCHOTIC, DOPAMINE ANTAGONIST, THIOXANTHE | THIOTHIXENE |
| A | H7R | ANTIPSYCHOTIC, DOPAMINE ANTAGONIST, DIPHENYLBUR | ORAP |
| A | H7S | ANTIPSYCHOTIC, DOPAMINE AND SEROTONIN ANTAGONI | MOBAN |
| A | H7T | ANTIPSYCHOTIC, ATYPICAL DOPAMINE AND SEROTONIN | RISPERDAL |
| A | H7U | ANTIPSYCHOTIC, DOPAMINE AND SEROTONIN ANTAGONI | LOXAPINE |
| D | H7W | ANTI-NARCOLEPSY/ANTI-CATAPLEXY, SEDATIVE-TYPE AGENT | XYREM |
| A | H7X | ANTIPSYCHOTICS, ATYPIC, D2 PARTIAL AGONIST/5HT MIXED | ABILIFY |
| PA | H7Y | TX FOR ATTN DEF-HYPERACTIV DISRDR (ADHD), NRI-TYPE | STRATTERA |

J AUTONOMIC NERVOUS SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|-----------------------|
| A | J1A | PARASYMPATHETIC AGENTS | URECHOLINE |
| PA | J1B | CHOLINESTERASE INHIBITORS | COGNEX |
| A | J2A | BELLADONNA ALKALOIDS | HYOSCYAMINE |
| A | J2B | ANTICHOLINERGICS, QUATERNARY | CLIDINIUM W/CHLORDIAZ |
| A | J2C | ANTICHOLINERGICS, OTHER | * |
| A | J2D | ANTICHOLINERGICS/ANTISPASMODICS | DICYCLOMINE HCL |
| D | J3A | GANGLIONIC STIMULANTS | NICOTROL |
| D | J4A | GANGLIONIC BLOCKING AGENTS | * |
| D | J5A | ADRENERGIC AGENTS, CATECHOLAMINES | DOPAMINE |
| D | J5B | ADRENERGICS, AROMATIC NON-CATECHOLAMINES (AMPHETAMINE) | DEXEDRINE |
| A | J5C | ADRENERGIC AGENTS, NON-AROMATIC | * |
| A | J5D | BETA-ADRENERGIC AGENTS | ALBUTEROL |
| A | J5E | SYMPATHOMIMETIC NASAL DECONGESTANTS | SUDAFED |
| A | J5F | ANAPHYLAXIS THERAPY AGENTS | ANA-KIT |
| A | J5G | BETA-ADRENERGICS AND GLUCOCORTICOID COMBINATIONS | ADVAIR DISKUS |
| A | J5H | ADRENERGIC VASOPRESSOR AGENTS | PROAMATINE |
| A | J7A | ALPHA/BETA ADRENERGIC BLOCKING AGENTS | TRANDATE |
| A | J7B | ALPHA-ADRENERGIC BLOCKING AGENTS | DIBENZYLINE |
| PA | J7C | BETA-ADRENERGIC BLOCKING AGENTS | PROPRANOLOL HCL |
| PA | J7E | ALPHA-ADRENERGIC BLOCKING AGENT/THIAZIDE COMB | MINIZIDE 1 |
| D | J8A | ANOREXIC AGENTS | PHENTERMINE |
| A | J9A | INTESTINAL MOTILITY STIMULANTS | METOCLOPRAMIDE HCL |
| PA | J9B | ANTISPASMODIC AGENTS | BEL-PHEN-ERGOT S |

L SKIN/SUBCUTANEOUS TISSUE

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| A | L0B | TOPICAL/MUCOUS MEMBRANE/SUB-Q ENZYME PREPS | SANTYL |
| PA | L0C | DIABETIC ULCER PREPARATIONS, TOPICAL | REGGRANEX |
| PA | L1A | ANTIPSORIATIC AGENTS, SYSTEMIC | SORIATANE |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| D | L1B | ACNE AGENTS, SYSTEMIC | ACCUTANE |
| D | L1C | HYPERTRICHOTIC AGENTS, SYSTEMIC | PROPECIA |
| D | L1D | HYPERPIGMENTATION AGENTS, SYSTEMIC | TRISORALEN |
| A | L2A | EMOLLIENTS | LAC-HYDRIN |
| A | L3A | PROTECTIVES | ZINC OXIDE |
| A | L3P | ANTIPRURITICS, TOPICAL | BENADRYL CREAM |
| A | L4A | ASTRINGENTS | WITCH HAZEL |
| D | L5A | KERATOLYTICS | DESQUAM-X 10% |
| D | L5B | SUNSCREENS | PRESUN SPF 15 |
| D | L5C | ABRASIVES | BRASIVOL |
| D | L5D | DEPILATORIES | SURGEX |
| D | L5E | ANTISEBORRHEIC AGENTS | SELSUN BLUE |
| PA | L5F | ANTIPSORIATIC AGENTS, TOPICAL | TAZORAC GEL |
| D | L5G | ROSACEA AGENTS, TOPICAL | FINACEA |
| D | L5H | ACNE AGENTS, TOPICAL | BENZACLIN |
| A | L5I | WOUND HEALING AGENTS, LOCAL | PVIDRM WND CARE SOL |
| PA | L5J | PHOTOACTIV, ANTINEOPLAS & PREMALIGNANT LESIONS | LEVULAN |
| A | L6A | IRRITANTS/COUNTER-IRRITANTS | CAPSAICIN |
| D | L7A | SHAMPOOS | |
| D | L8A | DEODORANTS | |
| D | L8B | ANTIPERSPIRANTS | |
| A | L9A | MISCELLANEOUS TOPICAL AGENTS | POLYTAR SOAP |
| D | L9B | VITAMIN A DERIVATIVES | RETIN-A |
| D | L9C | HYPOPIGMENTATION AGENTS | SOLAQUIN |
| D | L9D | TOPICAL HYPERPIGMENTATION AGENTS | OXSORALEN |
| D | L9F | COSMETIC/SKIN COLORING/DYE AGENTS, TOPICAL | VITADYE |
| D | L9G | SKIN TISSUE REPLACEMENT | APLIGRAF |
| D | L9I | VITAMIN A DERIVATIVES, TOPICAL COSMETIC AGENTS | RENOVA |
| D | L9J | HAIR GROWTH REDUCTION AGENTS | VANIQA |

M BLOOD

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|------------------------------------|-----------------------|
| PA | M0A | BLOOD COMPONENTS | * |
| PA | M0B | PLASMA PROTEINS | PLASMANATE 5% |
| PA | M0C | BLOOD FACTORS, MISCELLANEOUS | * |
| A | M0D | PLASMA EXPANDERS | DEXTRAN 40 |
| PA | M0E | ANTIHEMOPHILIC FACTORS | KOATE-HP |
| PA | M0F | FACTOR IX PREPARATIONS | KONYNE 80 |
| PA | M0G | ANTIPORPHYRIA FACTORS | PANHEMATIN |
| PA | M0H | FACTOR II PREPARATIONS | * |
| PA | M0R | BLOOD ALBUMIN PREPARATIONS | * |
| PA | M0S | SYNTHETIC BLOOD PREPARATIONS | * |
| D | M0U | BLOOD VOLUME DIAGNOSTICS | * |
| A | M3A | OCCULT BLOOD TESTS | GASTROCCULT |
| PA | M3B | BLOOD UREA NITROGEN TESTS | AZOSTIX REAGENT |
| PA | M4A | BLOOD SUGAR DIAGNOSTICS | ONE TOUCH TEST STRIPS |
| A | M4B | IV FAT EMULSIONS | LIPOSYN II |
| D | M4E | LIPOTROPICS | ZOCOR |
| D | M4G | HYPERGLYCEMICS | GLUCAGON |
| D | M4H | AGENTS THAT AFFECT CELLULAR LIPIDS | LIPITOR |
| A | M9A | TOPICAL HEMOSTATICS | THROMBOSTAT |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| A | M9D | ANTIFIBRINOLYTIC AGENTS | AMINOCAPROIC ACID |
| A | M9E | THROMBIN INHIBITORS, HIRUDIN TYPE AGENTS | REFLUDAN |
| A | M9F | THROMBOLYTIC ENZYMES | ABBOKINASE |
| A | M9J | CITRATES AS ANTICOAGULANTS | CITRATE PHOS DEXT |
| A | M9K | HEPARIN PREPARATIONS | HEPARIN |
| A | M9L | ORAL ANTICOAGULANTS, COUMARIN TYPE | COUMADIN |
| A | M9M | ORAL ANTICOAGULANTS, INDANDIONE TYPE | MIRADON |
| PA | M9P | PLATELET AGGREGATION INHIBITORS | TICLID |
| A | M9R | COAGULANTS | PROTAMINE |
| PA | M9S | HEMORRHEOLOGIC AGENTS | TRENTAL |
| D | M9T | THROMBIN INHIBITORS, SELECTIVE, DIRECT & REVERSIBLE | ARGATROBAN |

N BONE MARROW

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|-----------------------------------|---------------------|
| PA | N1A | ERYTHROID DEPRESSANTS | * |
| PA | N1B | HEMATINICS, OTHER | EPOGEN |
| D | N1C | LEUKOCYTE (WBC) STIMULANTS | NEUPOGEN |
| PA | N1D | PLATELET REDUCING AGENTS | AGRYLIN |
| PA | N1E | PLATELET PROLIFERATION STIMULANTS | NEUMEGA |

P ENDOCRINE SYSTEM (EXCEPT GONADS)

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| D | P0A | FERTILITY PREPARATIONS | CLOMIPHENE CITRATE |
| D | P0B | FOLLICLE STIMULATING HORMONES | HUMEGON |
| D | P0C | PREGNANCY FACILITATING/MAINTAINING AGTS, HORMONAL | CRINONE GEL |
| D | P1A | GROWTH HORMONES | GENOTROPIN |
| D | P1B | SOMATOSTATIC AGENTS | SANDOSTATIN |
| D | P1C | LUTEINIZING HORMONES | * |
| D | P1D | THYROTROPIC HORMONES | * |
| D | P1E | ADRENOCORTICOTROPHIC HORMONES | ACTHAR |
| D | P1F | PITUITARY SUPPRESSIVE AGENTS | DANOCRINE |
| D | P1G | ADRENAL STEROID INHIBITORS | CYTADREN |
| D | P1H | GROWTH HORMONE RELEASING HORMONE | GEREF |
| D | P1L | LUTEINIZING HORMONE RELEASING-HORMONE | FACTREL |
| D | P1M | LHRH/GNRH AGONIST ANALOG PITUITARY SUPPRESSANTS | SUPPRELIN |
| D | P1N | LHRH ANTAGONIST PITUITARY SUPPRESSANT AGENTS | CETROTIDE |
| D | P1P | LHRH/GNRH AGONIST PITUITARY SUPP-C PREC PUBERTY | LUPRON DEPOT-PED |
| D | P1Q | GROWTH HORMONE RECEPTOR ANTAGONISTS | SOMAVERT |
| D | P1U | METABOLIC FUNCTION DIAGNOSTICS | |
| D | P2B | ANTIIDIURETIC AND VASOPRESSOR HORMONES | DDAVP |
| D | P2Z | POSTERIOR PITUITARY PREPARATIONS | * |
| A | P3A | THYROID HORMONES | SYNTHYROID |
| D | P3B | THYROID FUNCTION DIAGNOSTIC AGENTS | THYREL TRH |
| D | P3L | ANTITHYROID PREPARATIONS | PROPYLTHIOURACIL |
| PA | P4A | PARATHYROID HORMONES | * |
| D | P4B | BONE FORM STIM AGENTS - PARATHYROID HORMONE-TYPE | FORTEO |
| PA | P4L | BONE RESORPTION SUPPRESSION AGENTS | FOSAMAX |
| A | P5A | GLUCOCORTICOIDS | PREDNISONE |
| A | P5S | MINERALOCORTICOIDS | FLORINEF ACETATE |
| A | P5T | ALDOSTERONE ANTAGONISTS | * |
| D | P6A | PINEAL HORMONE AGENTS | MELATONIN |

Q EAR, EYE, NOSE, RECTUM, TOPICAL, VAGINA, SPECIAL SENSES

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| A | Q0A | TOPICAL PREPARATIONS, NON-MEDICINAL | * |
| A | Q1A | TOPICAL EAR PREPARATIONS | * |
| D | Q2A | OCULAR PHOTOACTIVATED VESSEL-OCCLUDING AGENTS | VISUDYNE |
| D | Q2B | OPHTHALMIC SURGICAL AIDS | CELLUGEL |
| D | Q2C | OPHTHALMIC ANTI-INFLAMM IMMUNOMODULATOR-TYPE | RESTASIS |
| D | Q2U | EYE DIAGNOSTIC AGENTS | AK-FLUOR |
| A | Q3A | RECTAL PREPARATIONS | PROCTOFOAM-HC |
| A | Q3B | RECTAL/LOWER BOWEL PREP, GLUCOCORT, NON-HEMO | CORTIFOAM |
| A | Q3D | HEMORRHOIDAL PREPARATIONS | PREPARATION H |
| PA | Q3E | CHRONIC INFLM COLON DX 5 - AMINOSALICYLATES | ROWASA |
| A | Q3H | HEMORRHOIDAL PREPARATIONS, LOCAL ANESTHETICS | NUPERCAINAL OINT |
| A | Q3S | LAXATIVES, LOCAL/RECTAL | FLEET ENEMA |
| PA | Q4A | VAGINAL PREPARATIONS | PROSTIN E2 |
| PA | Q4B | VAGINAL ANTISEPTICS | BETADINE DOUCHE |
| PA | Q4F | VAGINAL ANTIFUNGALS | CLOTRIMAZOLE-7 |
| PA | Q4G | VAGINAL ANTIFUNGALS-ANTIBACTERIAL AGENTS | * |
| D | Q4K | VAGINAL ESTROGEN PREPARATIONS | ESTRACE CREAM |
| D | Q4L | VAGINAL LUBRICANT PREPARATIONS | ASTROGLIDE |
| PA | Q4R | VAGINAL ANTIPARASITICS | * |
| PA | Q4S | VAGINAL SULFONAMIDES | SULFANILAMIDE 15% |
| PA | Q4W | VAGINAL ANTIBIOTICS | CLEOCIN |
| D | Q5A | TOPICAL PREPARATIONS, MISCELLANEOUS | SHUR-CLENS |
| A | Q5B | TOPICAL PREPARATIONS, ANTIBACTERIALS | BETADINE |
| D | Q5C | TOPICAL PREPARATIONS, HYPERTRICHOTIC AGENTS | ROGAINE |
| PA | Q5D | TOPICAL PREPARATIONS, ANTIPSORIATICS | * |
| A | Q5E | TOPICAL ANTIINFLAMMATORY, NON-STEROIDAL | MSM W/GLUCOSAMINE |
| A | Q5F | TOPICAL ANTIFUNGALS | LOTRIMIN |
| A | Q5G | TOPICAL ANTIFUNGALS-ANTIBACTERIALS AGENTS | DIABET-X |
| A | Q5H | TOPICAL LOCAL ANESTHETICS | LIDOCAINE |
| PA | Q5I | TOPICAL VEINOTONIC/VASCULOPROTECTOR | * |
| D | Q5J | TOPICAL HORMONAL, OTHERWISE UNSPECIFIED | * |
| A | Q5K | TOPICAL IMMUNOSUPPRESSIVE AGENTS | ELIDEL |
| PA | Q5N | TOPICAL ANTINEOPLASTICS | EFUDEX 5% |
| A | Q5O | TOPICAL ANTIEDEMA/ANTIINFLAMMATORY AGENTS | * |
| A | Q5P | TOPICAL ANTIINFLAMMATORY PREPARATIONS | TRIAMCIN ACETONIDE |
| A | Q5Q | TOPICAL ANTIBIO-ANTIBAC-ANTIFUNG-ANTIINFLAMM AGENTS | * |
| A | Q5R | TOPICAL ANTIPARASITICS | LINDANE |
| A | Q5S | TOPICAL SULFONAMIDES | SILVADENE |
| A | Q5V | TOPICAL ANTIVIRALS | ZOVIRAX |
| A | Q5W | TOPICAL ANTIBIOTICS | NEOSPORIN |
| A | Q5X | TOPICAL ANTIBIOTICS/ANTIINFLAMMATORY, STEROIDAL | CORTISPORIN |
| D | Q5Y | TOPICAL ANDROGENIC AGENTS | DHEA |
| A | Q6A | EYE PREPARATIONS, MISCELLANEOUS | REFRESH P.M. |
| A | Q6B | EYE ANTIINFECTIVES (RX ONLY) | BETADINE EYE SOL |
| A | Q6C | EYE VASOCONSTRICTORS (RX ONLY) | PHENYLEPHRINE HCL |
| A | Q6D | EYE VASOCONSTRICTORS (OTC ONLY) | NAPHCON-A |
| A | Q6E | EYE IRRIGATIONS | BSS EYE SOLUTION |
| D | Q6F | CONTACT LENS PREPARATIONS | LENS PLUS |
| A | Q6G | MIOTICS AND OTHER INTRAOCULAR PRESSURE REDUCERS | TRUSOPT |
| A | Q6H | EYE LOCAL ANESTHETICS | TETRACAINE |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| A | Q6I | EYE ANTIBIOTIC-CORTICOID COMBINATIONS | TOBRADEX |
| A | Q6J | MYDRIATICS | CYCLOGYL |
| A | Q6K | OPHTHALMIC-OTIC COMBINATIONS | * |
| A | Q6P | EYE ANTIINFLAMMATORY AGENTS | ACULAR |
| A | Q6R | EYE ANTIHISTAMINES | PATANOL |
| A | Q6S | EYE SULFONAMIDES | SULFACETAMIDE NA |
| A | Q6T | ARTIFICIAL TEARS | ARTIFICIAL TEARS |
| A | Q6U | OPHTHALMIC MAST CELL STABILIZERS | CROMOLYN SODIUM |
| A | Q6V | EYE ANTIVIRALS | VIROPTIC |
| A | Q6W | EYE ANTIBIOTICS | GENTAMICIN SULFATE |
| A | Q6Y | EYE PREPARATIONS, MISCELLANEOUS (OTC ONLY) | LACRI-LUBE S.O.P. |
| A | Q6Z | EYE ANTIINFECTIVES, (OTC ONLY) | STYE |
| A | Q7A | NOSE PREPARATIONS, MISCELLANEOUS (RX ONLY) | ATROVENT |
| A | Q7B | NOSE PREPARATIONS, MISCELLANEOUS ANTIINFECTIVES | * |
| A | Q7C | NOSE PREPARATIONS, VASOCONSTRICTORS (RX ONLY) | TYZINE |
| A | Q7D | NOSE PREPARATIONS, VASOCONSTRICTORS (OTC ONLY) | AFRIN |
| A | Q7E | NASAL ANTIHISTAMINE | ASTELIN |
| A | Q7F | NASAL PREPARATIONS, ANTI-INFLAMMATORY-ANTIBIOTICS | * |
| A | Q7G | NASAL PREPARATIONS, IRRITANTS/COUNTER-IRRITANTS | AYR |
| A | Q7H | NASAL MAST CELL STABILIZERS AGENTS | NASALCROM |
| A | Q7P | NOSE PREPARATIONS, ANTIINFLAMMATORY | BECONASE AQ |
| A | Q7W | NOSE PREPARATIONS, ANTIBIOTICS | BACTROBAN |
| A | Q7Y | NOSE PREPARATIONS, MISCELLANEOUS (OTC ONLY) | NASAL SPRAY |
| A | Q8A | EAR PREPARATIONS, MISCELLANEOUS (RX ONLY) | OTO CARE HC |
| A | Q8B | EAR PREPARATIONS, MISCELLANEOUS ANTIINFECTIVES | DOMEBORO |
| A | Q8F | EAR PREPARATIONS, ANTI-INFLAMMATORY-ANTIBIOTICS | CIPRO HC |
| A | Q8H | EAR PREPARATIONS, LOCAL ANESTHETICS | AURALGAN |
| A | Q8P | EAR PREPARATIONS, ANTIINFLAMMATORY | EARSOL-HC |
| D | Q8R | EAR PREPARATIONS, EAR WAX REMOVERS | CERUMENEX |
| A | Q8W | EAR PREPARATIONS, ANTIBIOTICS | NEOMYCIN/PLYMYXN/HC |
| A | Q8Y | EAR PREPARATIONS, MISCELLANEOUS (OTC ONLY) | SWIM EAR DROPS |
| A | Q9A | UROLOGICAL IRRIGATIONS | * |
| D | Q9B | BENIGN PROSTATIC HYPERTROPHY/MICTURITION AGENTS | FLOMAX |

R KIDNEY/URINARY TRACT

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| A | R1A | URINARY TRACT ANTISPASMODIC AGENTS | OXYBUTYNIN CHLORIDE |
| PA | R1B | OSMOTIC DIURETICS | MANNITOL |
| PA | R1C | INORGANIC SALT DIURETICS | AMMONIUM CHLORIDE |
| PA | R1D | MERCURIAL DIURETICS | * |
| PA | R1E | CARBONIC ANHYDRASE INHIBITORS | DARANIDE |
| PA | R1F | THIAZIDE DIURETICS AND RELATED AGENTS | CHLOROTHIAZIDE |
| PA | R1H | POTASSIUM SPARING DIURETICS | MIDAMOR |
| PA | R1J | AMINOURACIL DIURETICS | * |
| PA | R1K | MISCELLANEOUS DIURETICS | ISMOTIC 45% |
| PA | R1L | POTASSIUM SPARING DIURETICS IN COMBINATION | DYAZIDE |
| PA | R1M | LOOP DIURETICS | FUROSEMIDE |
| D | R1R | URICOSURIC AGENTS | PROBENECID |
| A | R1S | URINARY PH MODIFIERS | RENACIDIN |
| A | R1T | RENAL COMPETERS | * |
| D | R1U | RENAL FUNCTION DIAGNOSTIC AGENTS | |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|---------------------|
| D | R2U | URINARY TRACT RADIOPAQUE DIAGNOSTICS | |
| PA | R3U | URINE GLUCOSE TEST AIDS | CHEMSTRIP UG |
| PA | R3V | MISCELLANEOUS URINE TEST AIDS | NITRAZINE PAPER |
| PA | R3W | URINE ACETONE TEST AIDS | ACETONE TEST STRIP |
| PA | R3Y | URINE MULTIPLE TEST AIDS | MULTISTIX 10 SG |
| PA | R3Z | URINE GLUC-ACET COMB.TST, STRIP | CHEMSTRIP UGK |
| PA | R4A | KIDNEY STONE AGENTS | THIOLA |
| PA | R5A | URINARY TRACT ANESTHETIC/ANALGESIC AGENTS | PHENAZOPYRIDINE |
| PA | R5B | URINARY TRACT ANALGESIC AGENTS | ELMIRON |

S LOCOMOTOR SYSTEM

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| D | S2A | COLCHICINE | COL-PROBENECID |
| A | S2B | NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE | IBUPROFEN |
| A | S2C | GOLD SALTS | RIDAURA |
| A | S2G | DRUGS ACTING ON BONE DISORDERS | * |
| PA | S2H | ANTI-INFLAMM/ANTIARTHRITIC AGENTS, MISCELLANEOUS | SYNVISIC |
| PA | S2I | ANTI-INFLAMM, PYRIMIDINE SYNTHESIS INHIBITOR | ARAVA |
| PA | S2J | ANTI-INFLAMM, TUMOR NECROSIS FACTOR INHIBITOR | ENBREL |
| PA | S2M | ANTI-INFLAMM INTERLEUKIN-1 RECPTR ANTAGONIST (IL-1A) | KINERET |
| PA | S2N | ANTI-ARTHRITIC, FOLATE ANTAGONIST AGENTS | RHEUMATREX |
| D | S7A | NEUROMUSCULAR BLOCKING AGENTS | BOTOX |
| A | S7B | SKELETAL MUSCLE, OTHERS | * |

U MISCELLANEOUS DRUGS AND PHARMACEUTICAL ADJUVANTS

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|---------------------|
| D | U5A | HOMEOPATHIC DRUGS | INSOMNIA FORMULA |
| D | U5B | HERBAL DRUGS | GINSENG |
| D | U5F | ANIMAL/HUMAN DERIVED AGENTS | NEATSFOOT |
| A | U6A | PHARMACEUTICAL ADJUVANTS, TABLETING AGENTS | STARCH |
| A | U6B | PHARMACEUTICAL ADJUVANTS, COATING AGENTS | * |
| A | U6C | THICKENING AGENTS | SOLUBLE STARCH |
| A | U6E | OINTMENT/CREAM BASES | PETROLEUM JELLY |
| A | U6F | HYDROPHILIC CREAM/OINTMENT BASES | UNIBASE OINTMENT |
| A | U6H | SOLVENTS | ISOPROPYL ALCOHOL |
| A | U6N | VEHICLES | SORBITOL |
| A | U6S | PROPELLANTS | * |
| A | U6W | BULK CHEMICALS, O.U. | PIROXICAM, BULK |
| A | U7A | SUSPENDING AGENTS | GELATIN |
| A | U7D | SURFACTANTS | LINDORA LIQUID |
| A | U7H | ANTIOXIDANTS | SULFUR |
| A | U7J | CHELATING AGENTS | GLUTATHIONE |
| A | U7K | FLAVORING AGENTS | ANISE |
| A | U7N | SWEETENERS | GLUCOSE |
| A | U7P | PERFUMES | LAVENDER OIL |
| A | U7Q | COLORING AGENTS | CAMEL |
| A | U7Z | BONDING/CATALYST AGENTS | |

V NEOPLASMS

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|-------------------------------|---------------------|
| PA | V1A | ALKYLATING AGENTS | CYTOXAN |
| PA | V1B | ANTIMETABOLITES | FLUOROURACIL |

| | | | |
|----|-----|--|---------------------|
| PA | V1C | VINCA ALKALOIDS | VINBLASTINE SULFATE |
| PA | V1D | ANTIBIOTIC ANTINEOPLASTICS | MUTAMYCIN |
| PA | V1E | STEROID ANTINEOPLASTICS | MEGACE |
| PA | V1F | MISCELLANEOUS ANTINEOPLASTICS | VEPESID |
| PA | V1G | RADIOACTIVE THERAPEUTIC AGENTS | METASTRON |
| PA | V1I | CHEMOTHERAPY ANTIDOTES | MESNEX |
| PA | V1J | ANTIANDROGENIC AGENTS | PROSCAR |
| PA | V1K | ANTINEOPLASTICS ANTIBODY/ANTIBODY-DRUG COMPLEXES | RITUXAN |
| PA | V1N | SELECTIVE RETINOID X RECEPTOR AGONISTS (RXR) | TARGRETIN |
| D | V1O | ANTINEOPLAST LHRH AGONISTS, PITUITARY SUPPRSSNT | ZOLADEX |
| PA | V1R | PHOTOACTIVATED, ANTINEOPLASTIC AGENTS, SYSTEMIC | PHOTOFRIN |
| PA | V1S | INTRAPLEURAL SCLEROS AGTS, ANTINEOPLASTIC ADJUVANT | SCLEROSOL |
| PA | V1T | SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERM) | FASLODEX |
| PA | V2A | NEOPLASM MONOCLONAL DIAGNOSTIC AGENTS | ONCOSCINT CR/OV |

W ANTI-INFECTING AGENTS

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|----------------------|
| A | W1A | PENICILLINS | AUGMENTIN |
| A | W1B | CEPHALOSPORINS | CEPHALEXIN |
| A | W1C | TETRACYCLINES | DOXYCYCLINE HYCLATE |
| A | W1D | MACROLIDES | ERY-TAB |
| A | W1E | CHLORAMPHENICOL AND DERIVATIVES | CHLORAMPHENICOL |
| A | W1F | AMINOGLYCOSIDES | GENTAMICIN |
| A | W1G | ANTITUBERCULAR ANTIBIOTICS | RIFADIN |
| A | W1H | AMINOCYCLITOLS | TROBICIN W/DILUENT |
| A | W1J | VANCOMYCIN AND DERIVATIVES | VANCOMYCIN HCL |
| A | W1K | LINCOSAMIDES | CLINDAMYCIN HCL |
| A | W1L | TOPICAL ANTIBIOTICS | BACITRACIN STER PWDR |
| A | W1M | STREPTOGRAMINS | SYNERCID |
| A | W1N | POLYMYXIN AND DERIVATIVES | POLYMYXIN B |
| A | W1O | OXAZOLIDONES | ZYVOX |
| A | W1P | OXABETA-LACTAMS | LORABID |
| A | W1Q | QUINOLONES | CIPRO |
| A | W1R | BETA-LACTAMASE INHIBITORS | * |
| A | W1S | THIENAMYCINS | PRIMAXIN I.V. |
| A | W1V | STEROIDAL ANTIBIOTICS | * |
| A | W1W | CEPHALOSPORINS-1ST GENERATION | CEPHALEXIN |
| A | W1X | CEPHALOSPORINS-2ND GENERATION | CEFUROXIME |
| A | W1Y | CEPHALOSPORINS-3RD GENERATION | ROCEPHIN |
| A | W1Z | CEPHALOSPORINS-4TH GENERATION | MAXIPIME |
| A | W2A | ABSORBABLE SULFONAMIDES | GANTANOL |
| A | W2B | NON-ABSORBABLE SULFONAMIDES | * |
| A | W2E | ANTITUBERCULAR AGENTS | ISONIAZID |
| A | W2F | NITROFURAN DERIVATIVES | PROSED/DS |
| A | W2G | ANTIBACTERIAL CHEMOTHERAPEUTIC AGENTS, MISC. | TRIMETHOPRIM |
| A | W2Y | MISCELLANEOUS ANTIINFECTIVES | DIMETHYL SULFOXIDE |
| A | W3A | ANTIFUNGAL ANTIBIOTICS | NYSTATIN |
| A | W3B | ANTIFUNGAL AGENTS | DIFLUCAN |
| A | W4A | ANTIMALARIAL DRUGS | QUININE SULFATE |
| D | W4C | AMEBACIDES | HUMATIN |
| A | W4E | TRICHOMONACIDES | METRONIDAZOLE |
| D | W4F | MISCELLANEOUS ANTIINFECTIVES (ANTIPARASITICS) | * |

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|---|-----------------------|
| D | W4K | MISCELLANEOUS ANTIPROTOZOAL DRUGS | PENTAMIDINE |
| D | W4L | ANTHELMINTICS | ALBENZA |
| D | W4M | TOPICAL ANTIPARASITICS | SULFUR |
| D | W4N | INSECT REPELLENTS | * |
| D | W4P | ANTILEPROTICS | LAMPRENE |
| D | W4Q | INSECTICIDES | BEDDING SPRAY |
| PA | W5A | ANTIVIRALS | VALTREX |
| A | W5C | ANTIVIRALS, HIV-SPECIFIC, PROTEASE INHIBITORS | CRIVAN |
| PA | W5D | ANTIVIRAL MONOCLONAL ANTIBODIES | SYNAGIS |
| PA | W5E | HEPATITIS A TREATMENT AGENTS | * |
| PA | W5F | HEPATITIS B TREATMENT AGENTS | EPIVIR HBV |
| PA | W5G | HEPATITIS C TREATMENT AGENTS | REBETRON 1000 |
| A | W5I | ANTIVIRALS, HIV-SPECIFIC, NUCLEOTIDE ANALOG, RVR INHIB | VIREAD |
| A | W5J | ANTIVIRALS, HIV-SPECIFIC, NUCLEOSIDE ANALOG, RVR INHIB | RETROVIR |
| A | W5K | ANTIVIRALS, HIV-SPEC, NON-NUCLEOSIDE REV TRANSCRIPT INHIB | VIRAMUNE |
| A | W5L | ANTIVIRALS, HIV-SPEC, NUCLEOSIDE ANALOG, RTI COMBOS | COMBIVIR |
| A | W5M | ANTIVIRALS, HIV –SPEC, PROTEASE INHIBITOR COMBOS | KALETRA |
| A | W5N | ANTIVIRALS, HIV-SPECIFIC, FUSION INHIBITORS | FUZEON |
| D | W6A | DRUGS TO TREAT SEPSIS SYNDROME, NON-ANTIBIOTIC | XIGRIS |
| D | W7B | EXANTHEMATOUS AND TUMOR CAUSING VIRUS VACCINES | RECOMBOVAX HB |
| D | W7C | INFLUENZA VIRUS VACCINES | OMNIBIB |
| D | W7F | MUMPS AND RELATED VIRUS VACCINES | MUMPSVAX |
| D | W7H | ENTERIC VIRUS VACCINES | ORIMUNE |
| D | W7I | IMMUNOSTIMULANTS, BACTERIAL | * |
| D | W7J | ARTHROPOD-BORNE AND OTHER NEUROTOX VIRUS VACCS | RABIES VACC |
| A | W7K | ANTISERA | H-BIG |
| D | W7L | GRAM POSITIVE COCCI VACCINES | PNU-IMUN |
| D | W7M | GRAM NEGATIVE BACILLI (NON-ENTERIC) VACCINES | TYPHOID VACC |
| D | W7N | TOXIN PRODUCING BACTERIA VACCINES AND TOXOIDS | CHOLERA VACC |
| D | W7O | GRAM POSITIVE ROD VACCINES | * |
| D | W7P | RICKETTSIAL VACCINES | * |
| D | W7Q | GRAM NEGATIVE COCCI VACCINES | MENOMUNE |
| D | W7R | SPIROCHETE VACCINES | LYMERIX |
| A | W7S | ANTIVENINS | ANTIVENIN, POLYVALENT |
| D | W7T | ANTIGENIC SKIN TESTS | TUBERCULINE TINE TEST |
| D | W7U | HYMENOPTERA EXTRACTS | ALBAY-MIX VESPID |
| D | W7V | RHUS EXTRACTS | SMPL SKIN DISRDRS #14 |
| D | W7W | MISCELLANEOUS THERAPEUTIC ALLERGENIC EXTRACTS | POLLEN EXTRACT |
| D | W7X | BACTERIA, AEROBIC/ANAEROBIC AGENTS | * |
| D | W7Y | FUNGI/YEAST PREPARATIONS | * |
| D | W7Z | COMBINATION VACCINE AND TOXOID PREPARATIONS | M-M-R II |
| A | W8A | HEAVY METAL ANTISEPTICS | MERCURY |
| A | W8B | SURFACE ACTIVE AGENTS | ZEPHIRAN |
| A | W8C | IODINE ANTISEPTICS | IODINE TINCTURE |
| A | W8D | OXIDIZING AGENTS | HYDROGEN PEROXIDE |
| A | W8E | ANTISEPTICS, GENERAL | ALCOHOL WIPES |
| A | W8F | IRRIGANTS | SODIUM CHLORIDE, .9% |
| D | W8G | MISCELLANEOUS ANTISEPTICS | CIDEX |
| D | W8H | MOUTHWASHES | CEPACOL |
| A | W8J | MISCELLANEOUS ANTIBACTERIAL AGENTS | GLYCINE, 1.5% |
| D | W8T | PRESERVATIVES | FORMALDEHYDE |

Z BODY AS A WHOLE

| STATUS | GC3 | THERAPEUTIC CLASS DESCRIPTION | REPRESENTATIVE DRUG |
|--------|-----|--|----------------------|
| D | Z1A | HISTAMINE PREPARATIONS | HISTATROL INTRDRML |
| D | Z1C | SEROTONIN AND DERIVATIVES | * |
| D | Z1D | ENZYME REPLACEMENTS (UBIQUITOUS ENZYMES) | CEREDASE |
| D | Z1E | ANTIOXIDANT AGENTS | ANTIOXIDANT A, C & E |
| PA | Z1F | IMMUNE SYSTEM CELL GROUPS | * |
| A | Z2A | ANTI HISTAMINES | DIPHENHYDRAMINE HCL |
| PA | Z2C | ANTISEROTONIN DRUGS | * |
| A | Z2D | HISTAMINE H2 INHIBITORS | * |
| PA | Z2E | IMMUNOSUPPRESIVES | SANDIMMUNE |
| A | Z2F | MAST CELL STABILIZERS | INTAL |
| PA | Z2G | IMMUNOMODULATORS | INTRON A |
| D | Z2H | SYSTEMIC ENZYME INHIBITORS | PROLASTIN |
| D | Z3G | MISCELLANEOUS AGENTS | KUTAPRESSIN |
| PA | Z4A | PROSTOGLANDINS | * |
| A | Z4B | LEUKOTRIENE RECEPTOR ANTAGONISTS | ACCOLATE |
| D | Z4C | THROMBOXANE A2 INHIBITORS | * |
| PA | Z4D | PROSTACYCLINS | * |
| D | Z9A | UNIDENTIFIED DRUGS | * |
| D | Z9D | DIAGNOSTIC PREPARATIONS, OU | PROVOCHOLINE |

APPENDIX H

DOCUMENTATION REQUIREMENTS⁽¹⁾

In addition to the documentation requirements published by the American Medical Association in the Physicians' Current Procedural Terminology book, the department or Self-Insurer has additional reporting and documentation requirements to adequately manage industrial insurance claims.

The department or self-insurer may request the following reports. No additional amount is payable for these reports as they are required to support billing. The department's Report of Accident or the Self-Insurer's Physician's Initial Report are payable separately. "Narrative report" as used in the table below merely signifies the absence of a specific form. Office/chart notes are expected to be legible and in the SOAP-ER format as specified under **CHARTING FORMAT**. Level of service is based on the documentation of services and the medical/clinical complexity as defined in the CPT Evaluation & Management (E/M) coding requirements.

| Service | Code(s) | Requirements |
|-------------------------------------|---------------------|--|
| Case Management and Telephone Calls | CPT® 99361-99373 | Documentation in the medical record should include: <ul style="list-style-type: none"> the date, the participants and their titles, the length of the call or visit, the nature of the call or visit, and any decisions made during the call. |
| Chiropractic Care Visit | Local 2050A & 2051A | Office/chart notes |
| | Local 2052A | Narrative report <u>or</u> office/chart notes showing the increased clinical complexity |
| Consultation | CPT® 99241-99275 | Narrative consultation report (WAC 296-20-051) <ul style="list-style-type: none"> due to the insurer within 15 days of consult |
| Critical Care | CPT® 99291 & 99292 | Narrative report <u>or</u> daily chart notes |
| Emergency Room | CPT® 99281 & 99282 | Report of accident <u>and</u> ER report/notes in the hospital medical record. |
| | CPT® 99283-99285 | Report of accident <u>and</u> ER report |
| Hospital | CPT® 99221-99223 | Report of accident <u>and</u> H&P |
| | CPT® 99231-99238 | Narrative report <u>or</u> an interval progress note |
| Nursing Facility | CPT® 99301-99303 | Narrative report <u>or</u> facility notes and orders |
| | CPT® 99311 | Narrative <u>or</u> an interval progress note |
| | CPT® 99312 & 99313 | Narrative report <u>or</u> facility notes and orders |
| Office Visit | CPT® 99201 & 99202 | Report of accident <u>and</u> office/chart notes due to the insurer in 5 days |
| | CPT® 99203-99205 | Report of accident <u>and</u> office/chart notes due to the insurer in 5 days |
| | CPT® 99211 & 99212 | Office/chart notes |
| | CPT® 99213-99215 | Narrative report <u>or</u> office/chart notes showing the increased level of complexity |
| Prolonged Services | CPT® 99354-99359 | Narrative <u>or</u> office/chart notes showing dates and times |
| Psychiatric Services | CPT® 90804-90853 | Narrative report |
| Standby | CPT® 99360 | Narrative <u>or</u> office/chart notes showing dates and times |
| Miscellaneous | CPT® 99288 & 99499 | Narrative report <u>or</u> emergency transport notes |

(1) See WAC 296-20-06101 for any additional information.